为了减少不安全的市场, FDA 将对药房使用进行评估. FDA to evaluate peptides for pharmacy use to reduce unsafe market.

美国食品和药物管理局计划评估七种受限制的类化合物的潜在使用, 这一举措得到了卫生部长罗伯特·肯尼迪小人的支持. The FDA plans to evaluate seven restricted peptides for potential use in compounding pharmacies, a move supported by Health Secretary Robert F. Kennedy Jr. to create a legal pathway and reduce reliance on the unsafe gray market. 虽然支持者认为这将改善质量控制,但专家警告说未经批准的仍然缺乏全面的安全数据. While advocates argue this would improve quality control, experts warn that unapproved peptides still lack comprehensive safety data.